Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2020-04-07 Major Shareholding Noti…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 162.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice under the Corporations Act 2001, specifically a "Notice of ceasing to be a substantial holder". It details changes in substantial shareholding interests, including dates, names, and share quantities. This type of filing is a notification of changes in major share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management information, but a regulatory notice about shareholding changes.
2020-04-07 English
Change in substantial holding 6 pages 182.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of Change of Interests of Substantial Holder filed under the Corporations Act 2001. It details changes in voting power and relevant interests of The Bank of New York Mellon Corporation and its group entities in Genetic Technologies Limited. The document includes dates of changes, previous and present voting power percentages, and annexures listing associated entities and securities affected. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory notice about shareholding changes.
2020-04-06 English
Prospectus Supplement to Form F-3 Registration Statement 61 pages 967.6KB
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the U.S. SEC by Genetic Technologies Limited, a foreign private issuer. It reports a definitive agreement for a registered direct offering of American Depositary Shares (ADSs) and includes detailed terms of the securities purchase agreement, placement agent agreement, and compensation warrants. The document contains legal opinions, agreements, and detailed descriptions of a capital raising transaction. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy, voting result, or governance document. The primary content is about a financing transaction and issuance of securities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual filing of the transaction, not just an announcement or press release. Confidence is high due to explicit references to securities purchase agreements and offering details.
2020-04-05 English
Prospectus Supplement to Prospectus dated March 23 2020 40 pages 956.1KB
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) and relates to an offering of securities by Genetic Technologies Limited. It includes detailed information about the offering, including the number of shares, pricing, risk factors, use of proceeds, and plan of distribution. The document references a shelf registration statement on Form F-3 and is clearly a disclosure document for a capital raising event. There is no indication that this is an annual report, earnings release, or any other type of financial report. Instead, it is a detailed capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2020-04-05 English
Appendix 3G 13 pages 247.8KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of new securities (warrants) as part consideration for placement agent services related to a capital raising. The document is a regulatory announcement about changes in the company's capital structure, specifically the issuance of new equity securities. It is not a full financial report, earnings release, or management discussion. It is also not a proxy, AGM material, or legal proceeding. The document fits the category of Capital/Financing Update (CAP) because it provides detailed information about new securities issued and related capital raising activities.
2020-04-05 English
Closing of US $1.8 Million Registered Direct Offering 2 pages 138.5KB
Capital/Financing Update Classification · 100% confidence The document is an ASX Market Announcement about the closing of a registered direct offering raising US $1.8 million. It details the capital raising, the number of shares issued, the price, and the intended use of proceeds. There is no financial report, earnings data, or detailed financial statements included. The document is a financing update announcing the completion of a capital raising transaction. The document length is short (2951 characters), and it is clearly an announcement of a financing event rather than a full report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-04-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.